Home > Boards > Stock Clubs > Long-Term > Billionaire Boys Club Member Forum (BBCMF)

What drugs will be available to treat COVID-19?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mick Member Profile
Member Level 
Followed By 2,624
Posts 863,737
Boards Moderated 191
Alias Born 09/04/00
160x600 placeholder
mick Member Level  Thursday, 03/26/20 12:26:39 PM
Re: mick post# 508113
Post # of 508932 
What drugs will be available to treat COVID-19? Here's a quick rundown and a timeline for when to expect them:

HOW MUCH WILL I GET? Use Our Stimulus Check Calculator
A lot of attention has been paid to existing antimalarials (in the chloroquine family) or flu drugs (favipiravir)

The antimalarials are in short supply, but production is ramping up. Mylan (MYL) and Teva Pharmaceuticals (TEVA) plan to jump-start production of hydroxychloroquine, which is also approved for treating lupus or rheumatoid arthritis. Teva says it will donate 6 million doses of hydroxychloroquine sulfate tablets tablets through wholesalers to hospitals by March 31. We expect them to be widely available in mid-April.

Remdesivir has been studied for years as an experimental antiviral, most recently for its potential against Ebola. Doctors were throwing it against COVID-19 in a "try something" approach, to the point that demand led its manufacturer, Gilead (GILD), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in mid-April, and two more in May.

One side effect of COVID-19 is a so-called "cytokine storm," in which the virus causes the immune system to overreact. Actemra by Roche (RHHBY) and Kevzara, by Sanofi (SNY) and Regeneron (REGN), are existing arthritis drugs which may also be able to counter a cytokine storm. Available in April.

SEE ALSO: 6 Med-Tech and Medical-Device Stocks to Buy
Convalescent plasma, blood plasma from patients who have recovered from the virus, with their antibodies in it. Still in research, availability at least nine months away.

Artificial antibodies, which are similar to blood plasma but more consistent. Trials should begin in early summer, availability possible in the early fall. Companies working on this idea: Regeneron, Eli Lilly (LLY) with AbCellera, Vir Biotechnology (VIR), and Biogen (BIIB).

EDITOR'S PICKS

10 Solid Social Distancing Stocks to Buy
24 Major U.S. Companies Hiring Now to Meet Coronavirus Demand
10 Coronavirus Stimulus Measures That Could Help You in 2020
Copyright 2020 The Kiplinger Washington Editors

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist